{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:43:09Z","timestamp":1769164989355,"version":"3.49.0"},"reference-count":202,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Probiotics &amp; Antimicro. Prot."],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12602-024-10431-z","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T10:34:05Z","timestamp":1735554845000},"page":"1688-1710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies"],"prefix":"10.1007","volume":"17","author":[{"given":"Maryam","family":"Sadri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Shafaghat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Roozbehani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Hoseinzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahimeh Lavi","family":"Arab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Minaeian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheil Rahmani","family":"Fard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Faraji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"10431_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-014-0145-y","volume":"12","author":"AA Mokdad","year":"2014","unstructured":"Mokdad AA et al (2014) Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 12:1\u201324","journal-title":"BMC Med"},{"issue":"1","key":"10431_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK et al (2019) Burden of liver diseases in the world. J Hepatol 70(1):151\u2013171","journal-title":"J Hepatol"},{"key":"10431_CR3","unstructured":"World Health Organization, Department of Mental Health, Substance Abuse (2004) Global status report on alcohol 2004. World Health Organization"},{"issue":"10027","key":"10431_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","volume":"387","author":"B Zhou","year":"2016","unstructured":"Zhou B et al (2016) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4\u00b7 4 million participants. Lancet 387(10027):1513\u20131530","journal-title":"Lancet"},{"issue":"10113","key":"10431_CR5","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","volume":"390","author":"L Abarca-G\u00f3mez","year":"2017","unstructured":"Abarca-G\u00f3mez L et al (2017) Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b7 9 million children, adolescents, and adults. Lancet 390(10113):2627\u20132642","journal-title":"Lancet"},{"issue":"1","key":"10431_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/07315724.2012.10720004","volume":"31","author":"IA Kirpich","year":"2012","unstructured":"Kirpich IA, McClain CJ (2012) Probiotics in the treatment of the liver diseases. J Am Coll Nutr 31(1):14\u201323","journal-title":"J Am Coll Nutr"},{"issue":"7","key":"10431_CR7","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3390\/microorganisms10071428","volume":"10","author":"GU Varela-Trinidad","year":"2022","unstructured":"Varela-Trinidad GU et al (2022) Probiotics: Protecting our health from the gut. Microorganisms 10(7):1428","journal-title":"Microorganisms"},{"issue":"2","key":"10431_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00253-021-11646-8","volume":"106","author":"MK Yadav","year":"2022","unstructured":"Yadav MK et al (2022) Probiotics, prebiotics and synbiotics: safe options for next-generation therapeutics. Appl Microbiol Biotechnol 106(2):505\u2013521","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"10431_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41538-020-00078-9","volume":"4","author":"AN Olaimat","year":"2020","unstructured":"Olaimat AN et al (2020) The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. npj Sci Food 4(1):17","journal-title":"npj Sci Food"},{"key":"10431_CR10","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.3389\/fmicb.2020.01877","volume":"11","author":"SK Tiwari","year":"2020","unstructured":"Tiwari SK et al (2020) Probiotics at war against viruses: what is missing from the picture? Front Microbiol 11:1877","journal-title":"Front Microbiol"},{"issue":"4","key":"10431_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.gastro.2014.07.056","volume":"147","author":"MM Yeh","year":"2014","unstructured":"Yeh MM, Brunt EM (2014) Pathological features of fatty liver disease. Gastroenterology 147(4):754\u2013764","journal-title":"Gastroenterology"},{"issue":"suppl","key":"10431_CR12","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","volume":"29","author":"SK Han","year":"2023","unstructured":"Han SK, Baik SK, Kim MY (2023) Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol 29(suppl):S5-s16","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"10431_CR13","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.3390\/nu11112642","volume":"11","author":"M Meroni","year":"2019","unstructured":"Meroni M, Longo M, Dongiovanni P (2019) The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies. Nutrients 11(11):2642","journal-title":"Nutrients"},{"issue":"1","key":"10431_CR14","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","volume":"9","author":"SB Ahn","year":"2019","unstructured":"Ahn SB et al (2019) Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep 9(1):5688","journal-title":"Sci Rep"},{"key":"10431_CR15","doi-asserted-by":"publisher","first-page":"558525","DOI":"10.3389\/fphar.2020.558525","volume":"11","author":"T Bao","year":"2020","unstructured":"Bao T et al (2020) Inulin exerts beneficial effects on non-alcoholic fatty liver disease via modulating gut microbiome and suppressing the lipopolysaccharide-toll-like receptor 4-M\u03c8-nuclear factor-\u03baB-Nod-like receptor protein 3 pathway via gut-liver axis in mice. Front Pharmacol 11:558525","journal-title":"Front Pharmacol"},{"issue":"8","key":"10431_CR16","doi-asserted-by":"publisher","first-page":"1700903","DOI":"10.1002\/mnfr.201700903","volume":"62","author":"YT Chen","year":"2018","unstructured":"Chen YT et al (2018) Sugary kefir strain Lactobacillus mali APS1 ameliorated hepatic steatosis by regulation of SIRT-1\/Nrf-2 and gut microbiota in rats. Mol Nutr Food Res 62(8):1700903","journal-title":"Mol Nutr Food Res"},{"issue":"3","key":"10431_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3920\/BM2016.0167","volume":"8","author":"X Li","year":"2017","unstructured":"Li X et al (2017) Effects of Lactobacillus casei CCFM419 on insulin resistance and gut microbiota in type 2 diabetic mice. Benefic Microbes 8(3):421\u2013432","journal-title":"Benefic Microbes"},{"issue":"2","key":"10431_CR18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/nu12020542","volume":"12","author":"E-J Park","year":"2020","unstructured":"Park E-J et al (2020) Beneficial effects of Lactobacillus plantarum strains on non-alcoholic fatty liver disease in high fat\/high fructose diet-fed rats. Nutrients 12(2):542","journal-title":"Nutrients"},{"issue":"6","key":"10431_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","volume":"35","author":"A Sepideh","year":"2016","unstructured":"Sepideh A et al (2016) Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial. J Am Coll Nutr 35(6):500\u2013505","journal-title":"J Am Coll Nutr"},{"issue":"6","key":"10431_CR20","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/ajcn\/nqy358","volume":"109","author":"Y Chen","year":"2019","unstructured":"Chen Y et al (2019) Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial. Am J Clin Nutr 109(6):1611\u20131619","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"10431_CR21","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2337\/db08-1637","volume":"58","author":"Z Gao","year":"2009","unstructured":"Gao Z et al (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58(7):1509\u20131517","journal-title":"Diabetes"},{"issue":"1","key":"10431_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jnutbio.2013.09.006","volume":"25","author":"G Mattace Raso","year":"2014","unstructured":"Mattace Raso G et al (2014) Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem 25(1):81\u201390","journal-title":"J Nutr Biochem"},{"issue":"21","key":"10431_CR23","doi-asserted-by":"publisher","first-page":"13436","DOI":"10.3390\/ijms232113436","volume":"23","author":"HT Nguyen","year":"2022","unstructured":"Nguyen HT et al (2022) Lactobacillus sakei MJM60958 as a potential probiotic alleviated non-alcoholic fatty liver disease in mice fed a high-fat diet by modulating lipid metabolism, inflammation, and gut microbiota. Int J Mol Sci 23(21):13436","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10431_CR24","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/microorganisms10112203","volume":"10","author":"P Werlinger","year":"2022","unstructured":"Werlinger P et al (2022) Lactobacillus reuteri MJM60668 prevent progression of non-alcoholic fatty liver disease through anti-adipogenesis and anti-inflammatory pathway. Microorganisms 10(11):2203","journal-title":"Microorganisms"},{"issue":"3","key":"10431_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/BF02977800","volume":"28","author":"S-Y Han","year":"2005","unstructured":"Han S-Y et al (2005) Hepatoprotective effect of lactic acid bacteria, inhibitors of \u03b2-glucuronidase production against intestinal microflora. Arch Pharmacal Res 28(3):325\u2013329","journal-title":"Arch Pharmacal Res"},{"issue":"6","key":"10431_CR26","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/hep.30975","volume":"71","author":"Y Liu","year":"2020","unstructured":"Liu Y et al (2020) Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice. Hepatology 71(6):2050\u20132066","journal-title":"Hepatology"},{"issue":"15","key":"10431_CR27","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1007\/s00253-014-5752-1","volume":"98","author":"J Xin","year":"2014","unstructured":"Xin J et al (2014) Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. Appl Microbiol Biotechnol 98(15):6817\u20136829","journal-title":"Appl Microbiol Biotechnol"},{"issue":"2","key":"10431_CR28","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1053\/j.gastro.2020.03.010","volume":"159","author":"CR Naudin","year":"2020","unstructured":"Naudin CR et al (2020) Lactococcus lactis subspecies cremoris elicits protection against metabolic changes induced by a western-style diet. Gastroenterology 159(2):639-651.e5","journal-title":"Gastroenterology"},{"issue":"2","key":"10431_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/microorganisms10020288","volume":"10","author":"J-J Jeong","year":"2022","unstructured":"Jeong J-J et al (2022) The Lactobacillus as a probiotic: focusing on liver diseases. Microorganisms 10(2):288","journal-title":"Microorganisms"},{"issue":"1","key":"10431_CR30","doi-asserted-by":"publisher","first-page":"e000315","DOI":"10.1136\/bmjgast-2019-000315","volume":"6","author":"A Duseja","year":"2019","unstructured":"Duseja A et al (2019) High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol 6(1):e000315","journal-title":"BMJ Open Gastroenterol"},{"issue":"12","key":"10431_CR31","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/1751-2980.12561","volume":"18","author":"E Manzhalii","year":"2017","unstructured":"Manzhalii E et al (2017) Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial. J Dig Dis 18(12):698\u2013703","journal-title":"J Dig Dis"},{"issue":"8","key":"10431_CR32","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/jn\/nxy088","volume":"148","author":"F Bakhshimoghaddam","year":"2018","unstructured":"Bakhshimoghaddam F et al (2018) Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Nutr 148(8):1276\u20131284","journal-title":"J Nutr"},{"issue":"3","key":"10431_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jhepr.2019.04.004","volume":"1","author":"KJ Schwenger","year":"2019","unstructured":"Schwenger KJ, Clermont-Dejean N, Allard JPJJR (2019) The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Reports 1(3):214\u2013226","journal-title":"JHEP Reports"},{"issue":"2","key":"10431_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/ijo.2017.210","volume":"42","author":"S Sherf-Dagan","year":"2018","unstructured":"Sherf-Dagan S et al (2018) Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial. Int J Obes 42(2):147\u2013155","journal-title":"Int J Obes"},{"key":"10431_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1146\/annurev.physiol.68.033104.152158","volume":"68","author":"NY Kalaany","year":"2006","unstructured":"Kalaany NY, Mangelsdorf DJ (2006) LXRS and FXR: the Yin and Yang of cholesterol and fat metabolism. Ann Rev Physiol 68:159\u2013191","journal-title":"Ann Rev Physiol"},{"issue":"12","key":"10431_CR36","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1007\/s10620-013-2879-3","volume":"58","author":"M Seo","year":"2013","unstructured":"Seo M et al (2013) Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats. Dig Dis Sci 58(12):3534\u20133544","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10431_CR37","doi-asserted-by":"publisher","first-page":"7386","DOI":"10.3168\/jds.2014-8500","volume":"97","author":"S Nabavi","year":"2014","unstructured":"Nabavi S et al (2014) Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci 97(12):7386\u20137393","journal-title":"J Dairy Sci"},{"key":"10431_CR38","doi-asserted-by":"publisher","first-page":"1617805","DOI":"10.1155\/2020\/1617805","volume":"2020","author":"A Gonzalez","year":"2020","unstructured":"Gonzalez A et al (2020) Role of oxidative stress in hepatic and extrahepatic dysfunctions during nonalcoholic fatty liver disease (NAFLD). Oxid Med Cell Longev 2020:1617805","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"10431_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, De Gottardi A, Rescigno M (2020) The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol 72(3):558\u2013577","journal-title":"J Hepatol"},{"issue":"3","key":"10431_CR40","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/biomedicines10030524","volume":"10","author":"Q Song","year":"2022","unstructured":"Song Q, Zhang X (2022) The role of gut\u2013liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines 10(3):524","journal-title":"Biomedicines"},{"issue":"2","key":"10431_CR41","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/biomedicines11020640","volume":"11","author":"N Ayob","year":"2023","unstructured":"Ayob N et al (2023) The effects of probiotics on small intestinal microbiota composition, inflammatory cytokines and intestinal permeability in patients with non-alcoholic fatty liver disease. Biomedicines 11(2):640","journal-title":"Biomedicines"},{"issue":"1","key":"10431_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13568-020-01038-y","volume":"10","author":"Y Yan","year":"2020","unstructured":"Yan Y et al (2020) Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease. AMB Express 10(1):101","journal-title":"AMB Express"},{"issue":"1","key":"10431_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12602-017-9378-3","volume":"11","author":"Y Liang","year":"2019","unstructured":"Liang Y et al (2019) Oral Administration of compound probiotics ameliorates HFD-induced gut microbe dysbiosis and chronic metabolic inflammation via the g protein-coupled receptor 43 in non-alcoholic fatty liver disease rats. Probiotics Antimicrob Proteins 11(1):175\u2013185","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"1","key":"10431_CR44","doi-asserted-by":"publisher","first-page":"45176","DOI":"10.1038\/srep45176","volume":"7","author":"L Xue","year":"2017","unstructured":"Xue L et al (2017) Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep 7(1):45176","journal-title":"Sci Rep"},{"issue":"1","key":"10431_CR45","doi-asserted-by":"publisher","first-page":"100769","DOI":"10.1016\/j.aohep.2022.100769","volume":"28","author":"STA Barcelos","year":"2023","unstructured":"Barcelos STA et al (2023) Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: a double-blind placebo-controlled randomized study. Ann Hepatol 28(1):100769","journal-title":"Ann Hepatol"},{"issue":"2","key":"10431_CR46","first-page":"147","volume":"38","author":"NA Osna","year":"2017","unstructured":"Osna NA, Donohue TM Jr, Kharbanda KK (2017) Alcoholic liver disease: pathogenesis and current management. Alcohol Res 38(2):147\u2013161","journal-title":"Alcohol Res"},{"key":"10431_CR47","doi-asserted-by":"crossref","unstructured":"Mishra G, et al (2023) Harnessing the potential of probiotics in the treatment of alcoholic liver disorders. Front Pharmacol 14","DOI":"10.3389\/fphar.2023.1212742"},{"issue":"4","key":"10431_CR48","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jnutbio.2014.10.016","volume":"26","author":"M Zhang","year":"2015","unstructured":"Zhang M et al (2015) Enhanced AMPK phosphorylation contributes to the beneficial effects of Lactobacillus rhamnosus GG supernatant on chronic-alcohol-induced fatty liver disease. J Nutr Biochem 26(4):337\u2013344","journal-title":"J Nutr Biochem"},{"key":"10431_CR49","doi-asserted-by":"crossref","unstructured":"Fang C, et al (2022) The AMPK pathway in fatty liver disease. Front Physiol 13","DOI":"10.3389\/fphys.2022.970292"},{"issue":"1","key":"10431_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.mam.2007.09.004","volume":"29","author":"E Albano","year":"2008","unstructured":"Albano E (2008) Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med 29(1):9\u201316","journal-title":"Mol Aspects Med"},{"issue":"1","key":"10431_CR51","doi-asserted-by":"publisher","first-page":"e53028","DOI":"10.1371\/journal.pone.0053028","volume":"8","author":"L Bull-Otterson","year":"2013","unstructured":"Bull-Otterson L et al (2013) Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS ONE 8(1):e53028","journal-title":"PLoS ONE"},{"issue":"6","key":"10431_CR52","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1016\/j.ajpath.2011.08.039","volume":"179","author":"Y Wang","year":"2011","unstructured":"Wang Y et al (2011) Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am J Pathol 179(6):2866\u20132875","journal-title":"Am J Pathol"},{"issue":"9","key":"10431_CR53","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.jnutbio.2013.02.001","volume":"24","author":"Y Wang","year":"2013","unstructured":"Wang Y et al (2013) Lactobacillus rhamnosus GG reduces hepatic TNF\u03b1 production and inflammation in chronic alcohol-induced liver injury. J Nutr Biochem 24(9):1609\u20131615","journal-title":"J Nutr Biochem"},{"issue":"1","key":"10431_CR54","doi-asserted-by":"publisher","first-page":"G32","DOI":"10.1152\/ajpgi.00024.2012","volume":"303","author":"Y Wang","year":"2012","unstructured":"Wang Y et al (2012) Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol-Gastrointest Liver Physiol 303(1):G32\u2013G41","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"10431_CR55","first-page":"270","volume":"33","author":"Y Wang","year":"2012","unstructured":"Wang Y et al (2012) Lactobacillus rhamnosus B10 treatment ameliorates ethanol-induced mouse liver injury by antioxidant pathways. Food Sci 33:270\u2013274","journal-title":"Food Sci"},{"issue":"8","key":"10431_CR56","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1111\/j.1572-0241.2002.05942.x","volume":"97","author":"C Loguercio","year":"2002","unstructured":"Loguercio C et al (2002) Gut-liver axis: a new point of attack to treat chronic liver damage? Off J Am Coll Gastroenterol | ACG 97(8):2144\u20132146","journal-title":"Off J Am Coll Gastroenterol | ACG"},{"issue":"12","key":"10431_CR57","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1097\/MEG.0b013e3282efa40e","volume":"19","author":"J Lata","year":"2007","unstructured":"Lata J et al (2007) The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 19(12):1111\u20131113","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"10431_CR58","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.alcohol.2008.08.006","volume":"42","author":"IA Kirpich","year":"2008","unstructured":"Kirpich IA et al (2008) Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 42(8):675\u2013682","journal-title":"Alcohol"},{"issue":"6","key":"10431_CR59","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/01.mcg.0000165671.25272.0f","volume":"39","author":"C Loguercio","year":"2005","unstructured":"Loguercio C et al (2005) Beneficial effects of a probiotic VSL# 3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 39(6):540\u2013543","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10431_CR60","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1053\/j.gastro.2014.08.031","volume":"147","author":"RK Dhiman","year":"2014","unstructured":"Dhiman RK et al (2014) Probiotic VSL# 3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 147(6):1327-1337. e3","journal-title":"Gastroenterology"},{"key":"10431_CR61","doi-asserted-by":"publisher","first-page":"671640","DOI":"10.3389\/fphar.2021.671640","volume":"12","author":"P Acharya","year":"2021","unstructured":"Acharya P et al (2021) Cellular mechanisms of liver fibrosis. Front Pharmacol 12:671640","journal-title":"Front Pharmacol"},{"issue":"1","key":"10431_CR62","doi-asserted-by":"publisher","first-page":"e1499","DOI":"10.1002\/wsbm.1499","volume":"13","author":"J Berumen","year":"2021","unstructured":"Berumen J et al (2021) Liver fibrosis: pathophysiology and clinical implications. WIREs Mech Dis 13(1):e1499","journal-title":"WIREs Mech Dis"},{"key":"10431_CR63","first-page":"e924040","volume":"26","author":"Q Zhang","year":"2020","unstructured":"Zhang Q et al (2020) Protective effect of probiotics against esophagogastric variceal rebleeding in patients with liver cirrhosis after endoscopic therapy. Med Sci Monit: Int Med J Exp Clin Res 26:e924040\u2013e924041","journal-title":"Med Sci Monit: Int Med J Exp Clin Res"},{"issue":"1","key":"10431_CR64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12602-020-09663-6","volume":"13","author":"C Jantararussamee","year":"2021","unstructured":"Jantararussamee C et al (2021) Hepatoprotective effect of probiotic lactic acid bacteria on thioacetamide-induced liver fibrosis in rats. Probiotics Antimicrob Proteins 13(1):40\u201350","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"3","key":"10431_CR65","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5487\/TR.2018.34.3.241","volume":"34","author":"YS Roh","year":"2018","unstructured":"Roh YS et al (2018) Lactobacillus aggravate bile duct ligation-induced liver inflammation and fibrosis in mice. Toxicol Res 34(3):241\u2013247","journal-title":"Toxicol Res"},{"issue":"9","key":"10431_CR66","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1177\/0300060518776064","volume":"46","author":"X Xia","year":"2018","unstructured":"Xia X et al (2018) Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. J Int Med Res 46(9):3596\u20133604","journal-title":"J Int Med Res"},{"issue":"4","key":"10431_CR67","doi-asserted-by":"publisher","first-page":"e0072","DOI":"10.1097\/HC9.0000000000000072","volume":"7","author":"L Laghi","year":"2023","unstructured":"Laghi L et al (2023) A multistrain probiotic increases the serum glutamine\/glutamate ratio in patients with cirrhosis: a metabolomic analysis. Hepatol Commun 7(4):e0072","journal-title":"Hepatol Commun"},{"issue":"5","key":"10431_CR68","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/hep4.1325","volume":"3","author":"E Rom\u00e1n","year":"2019","unstructured":"Rom\u00e1n E et al (2019) Effect of a multistrain probiotic on cognitive function and risk of falls in patients with cirrhosis: a randomized trial. Hepatol Commun 3(5):632\u2013645","journal-title":"Hepatol Commun"},{"issue":"6","key":"10431_CR69","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/nu12061651","volume":"12","author":"J Macnaughtan","year":"2020","unstructured":"Macnaughtan J et al (2020) A double-blind, randomized placebo-controlled trial of probiotic Lactobacillus casei Shirota in stable cirrhotic patients. Nutrients 12(6):1651","journal-title":"Nutrients"},{"issue":"6","key":"10431_CR70","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.3390\/nu12061874","volume":"12","author":"A Horvath","year":"2020","unstructured":"Horvath A et al (2020) Changes in the intestinal microbiome during a multispecies probiotic intervention in compensated cirrhosis. Nutrients 12(6):1874","journal-title":"Nutrients"},{"key":"10431_CR71","doi-asserted-by":"publisher","first-page":"e00439","DOI":"10.1016\/j.idcr.2018.e00439","volume":"13","author":"SSB Naqvi","year":"2018","unstructured":"Naqvi SSB, Nagendra V, Hofmeyr A (2018) Probiotic related Lactobacillus rhamnosus endocarditis in a patient with liver cirrhosis. IDCases 13:e00439","journal-title":"IDCases"},{"key":"10431_CR72","doi-asserted-by":"crossref","unstructured":"Ramachandran L, Dontaraju VS, Patel K (2020) Lactobacillus-associated spontaneous bacterial peritonitis in a liver cirrhosis patient on probiotics. Cureus 12(12)","DOI":"10.7759\/cureus.11896"},{"key":"10431_CR73","doi-asserted-by":"publisher","first-page":"1104399","DOI":"10.3389\/fcimb.2022.1104399","volume":"12","author":"K Shi","year":"2023","unstructured":"Shi K et al (2023) Association between probiotic therapy and the risk of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis. Front Cell Infect Microbiol 12:1104399","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10431_CR74","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.hbpd.2018.11.002","volume":"18","author":"J-W Jiang","year":"2019","unstructured":"Jiang J-W et al (2019) Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis. Hepatobiliary Pancreat Dis Int 18(1):19\u201327","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"5","key":"10431_CR75","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.3390\/ijms22052606","volume":"22","author":"WPDW Thilakarathna","year":"2021","unstructured":"Thilakarathna WPDW, Rupasinghe HPV, Ridgway ND (2021) Mechanisms by which probiotic bacteria attenuate the risk of hepatocellular carcinoma. Int J Mol Sci 22(5):2606","journal-title":"Int J Mol Sci"},{"key":"10431_CR76","doi-asserted-by":"publisher","first-page":"149","DOI":"10.17582\/journal.pujz\/2019.34.2.149.158","volume":"34","author":"S Ali","year":"2019","unstructured":"Ali S et al (2019) Hepatocellular carcinomas risk factors, diagnosis, prevention and frontier to probiotic treatment. Punjab Univ J Zool 34:149\u2013158","journal-title":"Punjab Univ J Zool"},{"issue":"4","key":"10431_CR77","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/01.SLA.0000059988.22416.F2","volume":"237","author":"G Ercolani","year":"2003","unstructured":"Ercolani G et al (2003) Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 237(4):536\u2013543","journal-title":"Ann Surg"},{"key":"10431_CR78","doi-asserted-by":"publisher","first-page":"4750795","DOI":"10.1155\/2019\/4750795","volume":"2019","author":"HPV Rupasinghe","year":"2019","unstructured":"Rupasinghe HPV, Parmar I, Neir SV (2019) Biotransformation of cranberry proanthocyanidins to probiotic metabolites by <i>Lactobacillus rhamnosus<\/i> enhances their anticancer activity in HepG2 cells <i>in vitro<\/i>. Oxid Med Cell Longev 2019:4750795","journal-title":"Oxid Med Cell Longev"},{"key":"10431_CR79","doi-asserted-by":"publisher","first-page":"873160","DOI":"10.3389\/fmicb.2022.873160","volume":"13","author":"W Luo","year":"2022","unstructured":"Luo W et al (2022) Hepatocellular carcinoma: how the gut microbiota contributes to pathogenesis, diagnosis, and therapy. Front Microbiol 13:873160","journal-title":"Front Microbiol"},{"issue":"2","key":"10431_CR80","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/vaccines8020329","volume":"8","author":"G Aindelis","year":"2020","unstructured":"Aindelis G, Chlichlia K (2020) Modulation of anti-tumour immune responses by probiotic bacteria. Vaccines 8(2):329","journal-title":"Vaccines"},{"issue":"5","key":"10431_CR81","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","volume":"60","author":"JS Bajaj","year":"2014","unstructured":"Bajaj JS et al (2014) Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60(5):940\u2013947","journal-title":"J Hepatol"},{"issue":"01","key":"10431_CR82","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/gut.2009.183749","volume":"59","author":"JG Fox","year":"2010","unstructured":"Fox JG et al (2010) Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59(01):88\u201397","journal-title":"Gut"},{"issue":"4","key":"10431_CR83","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/hep.23845","volume":"52","author":"L-X Yu","year":"2010","unstructured":"Yu L-X et al (2010) Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52(4):1322\u20131333","journal-title":"Hepatology"},{"issue":"4","key":"10431_CR84","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","volume":"21","author":"DH Dapito","year":"2012","unstructured":"Dapito DH et al (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21(4):504\u2013516","journal-title":"Cancer Cell"},{"issue":"2","key":"10431_CR85","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jhep.2012.08.019","volume":"58","author":"M Darnaud","year":"2013","unstructured":"Darnaud M, Faivre J, Moniaux N (2013) Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol 58(2):385\u2013387","journal-title":"J Hepatol"},{"issue":"6","key":"10431_CR86","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/gutjnl-2017-315084","volume":"68","author":"Z Ren","year":"2019","unstructured":"Ren Z et al (2019) Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 68(6):1014\u20131023","journal-title":"Gut"},{"issue":"1","key":"10431_CR87","doi-asserted-by":"publisher","first-page":"33142","DOI":"10.1038\/srep33142","volume":"6","author":"H Lu","year":"2016","unstructured":"Lu H et al (2016) Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma. Sci Rep 6(1):33142","journal-title":"Sci Rep"},{"issue":"5","key":"10431_CR88","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.transproceed.2016.01.077","volume":"48","author":"M Gr\u0105t","year":"2016","unstructured":"Gr\u0105t M et al (2016) Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. Transpl Proc 48(5):1687\u20131691","journal-title":"Transpl Proc"},{"issue":"4","key":"10431_CR89","doi-asserted-by":"publisher","first-page":"62","DOI":"10.7812\/TPP\/12-144","volume":"17","author":"V Sharma","year":"2013","unstructured":"Sharma V, Garg S, Aggarwal S (2013) Probiotics and liver disease. Permanente J 17(4):62","journal-title":"Permanente J"},{"issue":"8","key":"10431_CR90","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1157\/13127094","volume":"31","author":"P Bellot","year":"2008","unstructured":"Bellot P, Franc\u00e9s R, Such J (2008) Bacterial translocation in cirrhosis. Gastroenterol Hepatol 31(8):508\u2013514","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"10431_CR91","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","volume":"54","author":"Y Chen","year":"2011","unstructured":"Chen Y et al (2011) Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54(2):562\u2013572","journal-title":"Hepatology"},{"issue":"6","key":"10431_CR92","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/cid\/ciy205","volume":"67","author":"T Inoue","year":"2018","unstructured":"Inoue T et al (2018) Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis 67(6):869\u2013877","journal-title":"Clin Infect Dis"},{"key":"10431_CR93","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.eng.2022.12.012","volume":"29","author":"Z Xiang","year":"2023","unstructured":"Xiang Z et al (2023) Gut microbiota modulation: a viable strategy to address medical needs in hepatocellular carcinoma and liver transplantation. Engineering 29:59\u201372","journal-title":"Engineering"},{"issue":"4","key":"10431_CR94","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jhep.2012.06.011","volume":"57","author":"H-L Zhang","year":"2012","unstructured":"Zhang H-L et al (2012) Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol 57(4):803\u2013812","journal-title":"J Hepatol"},{"issue":"6","key":"10431_CR95","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/01.mcg.0000165671.25272.0f","volume":"39","author":"C Loguercio","year":"2005","unstructured":"Loguercio C et al (2005) Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases. J Clin Gastroenterol 39(6):540\u2013543","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10431_CR96","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1757-4749-1-19","volume":"1","author":"EP Culligan","year":"2009","unstructured":"Culligan EP, Hill C, Sleator RD (2009) Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathogens 1(1):19","journal-title":"Gut Pathogens"},{"issue":"3","key":"10431_CR97","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.gtc.2005.05.002","volume":"34","author":"S Bengmark","year":"2005","unstructured":"Bengmark S (2005) Bioecologic control of the gastrointestinal tract: the role of flora and supplemented probiotics and synbiotics. Gastroenterol Clin 34(3):413\u2013436","journal-title":"Gastroenterol Clin"},{"issue":"1","key":"10431_CR98","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000380895","volume":"2","author":"X Tao","year":"2015","unstructured":"Tao X, Wang N, Qin W (2015) Gut microbiota and hepatocellular carcinoma. Gastrointest Tumors 2(1):33\u201340","journal-title":"Gastrointest Tumors"},{"issue":"1","key":"10431_CR99","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hep.30036","volume":"69","author":"FR Ponziani","year":"2019","unstructured":"Ponziani FR et al (2019) Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 69(1):107\u2013120","journal-title":"Hepatology"},{"issue":"4","key":"10431_CR100","first-page":"958","volume":"11","author":"L Zhang","year":"2023","unstructured":"Zhang L, Yang L, Chu H (2023) Targeting gut microbiota for the treatment of primary biliary cholangitis: from bench to bedside. J Clin Transl Hepatol 11(4):958\u2013966","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"10431_CR101","doi-asserted-by":"publisher","first-page":"295","DOI":"10.21037\/hbsn.2019.01.16","volume":"8","author":"A Nicoletti","year":"2019","unstructured":"Nicoletti A et al (2019) Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma. Hepatobiliary Surg Nutr 8(3):295\u2013297","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"10431_CR102","doi-asserted-by":"publisher","first-page":"e7521","DOI":"10.5812\/hepatmon.7521","volume":"13","author":"AA Imani Fooladi","year":"2013","unstructured":"Imani Fooladi AA et al (2013) Probiotic as a novel treatment strategy against liver disease. Hepat Mon 13(2):e7521","journal-title":"Hepat Mon"},{"issue":"9","key":"10431_CR103","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cgh.2012.03.024","volume":"10","author":"MA Ciorba","year":"2012","unstructured":"Ciorba MA (2012) A gastroenterologist\u2019s guide to probiotics. Clin Gastroenterol Hepatol 10(9):960\u2013968","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10431_CR104","doi-asserted-by":"publisher","first-page":"665","DOI":"10.18388\/abp.2005_3428","volume":"52","author":"W Grajek","year":"2005","unstructured":"Grajek W, Olejnik A, Sip A (2005) Probiotics, prebiotics and antioxidants as functional foods. Acta Biochim Pol 52(3):665\u2013671","journal-title":"Acta Biochim Pol"},{"issue":"4","key":"10431_CR105","first-page":"740","volume":"7","author":"M Aghajanpour","year":"2017","unstructured":"Aghajanpour M et al (2017) Functional foods and their role in cancer prevention and health promotion: a comprehensive review. Am J Cancer Res 7(4):740\u2013769","journal-title":"Am J Cancer Res"},{"issue":"9","key":"10431_CR106","doi-asserted-by":"publisher","first-page":"E1306","DOI":"10.1073\/pnas.1518189113","volume":"113","author":"J Li","year":"2016","unstructured":"Li J et al (2016) Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci 113(9):E1306\u2013E1315","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10431_CR107","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/j.1478-3231.2009.02020.x","volume":"29","author":"P Tandon","year":"2009","unstructured":"Tandon P et al (2009) Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int 29(7):1110\u20131115","journal-title":"Liver Int"},{"issue":"10","key":"10431_CR108","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1111\/liv.12539","volume":"34","author":"D Rinc\u00f3n","year":"2014","unstructured":"Rinc\u00f3n D et al (2014) Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver Int 34(10):1504\u20131512","journal-title":"Liver Int"},{"key":"10431_CR109","doi-asserted-by":"publisher","first-page":"666","DOI":"10.12659\/MSM.912840","volume":"25","author":"Z Zhou","year":"2019","unstructured":"Zhou Z et al (2019) The association between vitamin d status, vitamin d supplementation, sunlight exposure, and Parkinson\u2019s disease: a systematic review and meta-analysis. Med Sci Monit 25:666\u2013674","journal-title":"Med Sci Monit"},{"issue":"9","key":"10431_CR110","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/17474124.2017.1343663","volume":"11","author":"T Preveden","year":"2017","unstructured":"Preveden T et al (2017) Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 11(9):813\u2013819","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"10431_CR111","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jhep.2008.12.033","volume":"50","author":"J-P Zhang","year":"2009","unstructured":"Zhang J-P et al (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50(5):980\u2013989","journal-title":"J Hepatol"},{"issue":"1","key":"10431_CR112","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajpath.2012.08.041","volume":"182","author":"J Ye","year":"2013","unstructured":"Ye J, Livergood RS, Peng G (2013) The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 182(1):10\u201320","journal-title":"Am J Pathol"},{"issue":"1","key":"10431_CR113","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-9966-32-3","volume":"32","author":"R Liao","year":"2013","unstructured":"Liao R et al (2013) High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res 32(1):3","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10431_CR114","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.immuni.2016.09.009","volume":"45","author":"R Daill\u00e8re","year":"2016","unstructured":"Daill\u00e8re R et al (2016) <em>Enterococcus hirae<\/em> and <em>Barnesiella intestinihominis<\/em> Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity 45(4):931\u2013943","journal-title":"Immunity"},{"issue":"3","key":"10431_CR115","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/01635581.2021.1934490","volume":"74","author":"OMS Khedr","year":"2022","unstructured":"Khedr OMS et al (2022) Lactobacillus acidophilus ATCC 4356 exopolysaccharides suppresses mediators of inflammation through the inhibition of TLR2\/STAT-3\/P38-MAPK pathway in DEN-induced hepatocarcinogenesis in rats. Nutr Cancer 74(3):1037\u20131047","journal-title":"Nutr Cancer"},{"issue":"1","key":"10431_CR116","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12934-017-0691-z","volume":"16","author":"JG LeBlanc","year":"2017","unstructured":"LeBlanc JG et al (2017) Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb Cell Fact 16(1):79","journal-title":"Microb Cell Fact"},{"issue":"3","key":"10431_CR117","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1113\/jphysiol.2011.219691","volume":"590","author":"E Seki","year":"2012","unstructured":"Seki E, Schnabl B (2012) Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 590(3):447\u2013458","journal-title":"J Physiol"},{"issue":"1","key":"10431_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12303","volume":"1306","author":"B Petschow","year":"2013","unstructured":"Petschow B et al (2013) Probiotics, prebiotics, and the host microbiome: the science of translation. Ann N Y Acad Sci 1306(1):1\u201317","journal-title":"Ann N Y Acad Sci"},{"key":"10431_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jff.2018.11.050","volume":"53","author":"SA dos Reis","year":"2019","unstructured":"dos Reis SA et al (2019) Kefir reduces the incidence of pre-neoplastic lesions in an animal model for colorectal cancer. J Funct Foods 53:1\u20136","journal-title":"J Funct Foods"},{"issue":"5","key":"10431_CR120","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/09637480903455971","volume":"61","author":"M Kumar","year":"2010","unstructured":"Kumar M et al (2010) Cancer-preventing attributes of probiotics: an update. Int J Food Sci Nutr 61(5):473\u2013496","journal-title":"Int J Food Sci Nutr"},{"issue":"7","key":"10431_CR121","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1017\/S0007114511003953","volume":"107","author":"M Kumar","year":"2011","unstructured":"Kumar M et al (2011) Anticarcinogenic effect of probiotic fermented milk and chlorophyllin on aflatoxin-B1-induced liver carcinogenesis in rats. Br J Nutr 107(7):1006\u20131016","journal-title":"Br J Nutr"},{"issue":"12","key":"10431_CR122","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1093\/carcin\/bgg167","volume":"24","author":"M Zsivkovits","year":"2003","unstructured":"Zsivkovits M et al (2003) Prevention of heterocyclic amine-induced DNA damage in colon and liver of rats by different lactobacillus strains. Carcinogenesis 24(12):1913\u20131918","journal-title":"Carcinogenesis"},{"issue":"11","key":"10431_CR123","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.1128\/AEM.01348-06","volume":"72","author":"S Gratz","year":"2006","unstructured":"Gratz S et al (2006) <i>Lactobacillus rhamnosus<\/i> strain GG modulates intestinal absorption, fecal excretion, and toxicity of aflatoxin B<sub>1<\/sub> in rats. Appl Environ Microbiol 72(11):7398\u20137400","journal-title":"Appl Environ Microbiol"},{"issue":"5","key":"10431_CR124","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/ajcn\/83.5.1199","volume":"83","author":"HS El-Nezami","year":"2006","unstructured":"El-Nezami HS et al (2006) Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China2. Am J Clin Nutr 83(5):1199\u20131203","journal-title":"Am J Clin Nutr"},{"key":"10431_CR125","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijbiomac.2013.10.036","volume":"63","author":"K Wang","year":"2014","unstructured":"Wang K et al (2014) Characterization of a novel exopolysaccharide with antitumor activity from Lactobacillus plantarum 70810. Int J Biol Macromol 63:133\u2013139","journal-title":"Int J Biol Macromol"},{"issue":"11","key":"10431_CR126","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1111\/1750-3841.13921","volume":"82","author":"P Shokryazdan","year":"2017","unstructured":"Shokryazdan P et al (2017) In vitro assessment of bioactivities of lactobacillus strains as potential probiotics for humans and chickens. J Food Sci 82(11):2734\u20132745","journal-title":"J Food Sci"},{"key":"10431_CR127","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tice.2019.07.010","volume":"60","author":"AM Elshaer","year":"2019","unstructured":"Elshaer AM et al (2019) Involvement of TLR4\/ CXCL9\/ PREX-2 pathway in the development of hepatocellular carcinoma (HCC) and the promising role of early administration of lactobacillus plantarum in Wistar rats. Tissue Cell 60:38\u201347","journal-title":"Tissue Cell"},{"issue":"6","key":"10431_CR128","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.clnu.2016.11.017","volume":"36","author":"S Dasari","year":"2017","unstructured":"Dasari S et al (2017) Surfacing role of probiotics in cancer prophylaxis and therapy: A systematic review. Clin Nutr 36(6):1465\u20131472","journal-title":"Clin Nutr"},{"key":"10431_CR129","doi-asserted-by":"publisher","first-page":"100096","DOI":"10.1016\/j.jnim.2019.100096","volume":"16","author":"Z Heydari","year":"2019","unstructured":"Heydari Z, Rahaie M, Alizadeh AM (2019) Different anti-inflammatory effects of Lactobacillus acidophilus and Bifidobactrum bifidioum in hepatocellular carcinoma cancer mouse through impact on microRNAs and their target genes. J Nutr Intermediary Metab 16:100096","journal-title":"J Nutr Intermediary Metab"},{"key":"10431_CR130","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jff.2017.09.033","volume":"38","author":"M Mihailovi\u0107","year":"2017","unstructured":"Mihailovi\u0107 M et al (2017) Oral administration of probiotic Lactobacillus paraplantarum BGCG11 attenuates diabetes-induced liver and kidney damage in rats. J Funct Foods 38:427\u2013437","journal-title":"J Funct Foods"},{"key":"10431_CR131","doi-asserted-by":"publisher","unstructured":"Lv L, et al (2021) Lactobacillus acidophilus LA14 alleviates liver injury. mSystems 6(3).https:\/\/doi.org\/10.1128\/msystems.00384-21","DOI":"10.1128\/msystems.00384-21"},{"key":"10431_CR132","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3389\/fgene.2019.00638","volume":"10","author":"J Miro-Blanch","year":"2019","unstructured":"Miro-Blanch J, Yanes O (2019) Epigenetic regulation at the interplay between gut microbiota and host metabolism. Front Genet 10:638","journal-title":"Front Genet"},{"issue":"1","key":"10431_CR133","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.gene.2011.09.003","volume":"490","author":"M Kumar","year":"2011","unstructured":"Kumar M et al (2011) Effect of probiotic fermented milk and chlorophyllin on gene expressions and genotoxicity during AFB1-induced hepatocellular carcinoma. Gene 490(1):54\u201359","journal-title":"Gene"},{"issue":"15","key":"10431_CR134","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.3390\/ijms22157800","volume":"22","author":"S Temraz","year":"2021","unstructured":"Temraz S et al (2021) Hepatocellular carcinoma immunotherapy and the potential influence of gut microbiome. Int J Mol Sci 22(15):7800","journal-title":"Int J Mol Sci"},{"key":"10431_CR135","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.semcancer.2017.08.007","volume":"46","author":"L Marinelli","year":"2017","unstructured":"Marinelli L, Tenore GC, Novellino E (2017) Probiotic species in the modulation of the anticancer immune response. Semin Cancer Biol 46:182\u2013190","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10431_CR136","first-page":"208","volume":"64","author":"Z Rifatbegovic","year":"2010","unstructured":"Rifatbegovic Z et al (2010) Effect of probiotics on liver function after surgery resection for malignancy in the liver cirrhotic. Med Arch 64(4):208","journal-title":"Med Arch"},{"issue":"3","key":"10431_CR137","doi-asserted-by":"publisher","first-page":"123","DOI":"10.12938\/bmfh.2015-024","volume":"35","author":"KM Oo","year":"2016","unstructured":"Oo KM et al (2016) Safety and long-term effect of the probiotic FK-23 in patients with hepatitis C virus infection. Biosci Microbiota, Food Health 35(3):123\u2013128","journal-title":"Biosci Microbiota, Food Health"},{"key":"10431_CR138","doi-asserted-by":"publisher","first-page":"1179014","DOI":"10.3389\/fimmu.2023.1179014","volume":"14","author":"S Chen","year":"2023","unstructured":"Chen S et al (2023) Lactobacillus brevis alleviates the progress of hepatocellular carcinoma and type 2 diabetes in mice model via interplay of gut microflora, bile acid and NOTCH 1 signaling. Front Immunol 14:1179014","journal-title":"Front Immunol"},{"issue":"7","key":"10431_CR139","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1039\/C5FO00248F","volume":"6","author":"P Hu","year":"2015","unstructured":"Hu P et al (2015) Lactobacillus paracasei subsp. paracasei M5L induces cell cycle arrest and calreticulin translocation via the generation of reactive oxygen species in HT-29 cell apoptosis. Food Funct 6(7):2257\u20132265","journal-title":"Food Funct"},{"key":"10431_CR140","unstructured":"Aminaei M, et al (2018) Primary evidence on the potential of Lactobacillus paracasei in treatment of hepatocellular carcinoma"},{"key":"10431_CR141","first-page":"1","volume":"6","author":"BD Karlton-Senaye","year":"2017","unstructured":"Karlton-Senaye BD et al (2017) Lactobacillus rhamnosus GG Inhibits BID dependent-apoptosis in human hepatocellular carcinoma cells exposed to patulin. J Field Robot 6:1","journal-title":"J Field Robot"},{"key":"10431_CR142","doi-asserted-by":"crossref","unstructured":"Hill C, et al (2014) Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol","DOI":"10.1038\/nrgastro.2014.66"},{"issue":"7","key":"10431_CR143","doi-asserted-by":"publisher","first-page":"e24512","DOI":"10.1002\/jcla.24512","volume":"36","author":"K Li","year":"2022","unstructured":"Li K, Liu J, Qin X (2022) Research progress of gut microbiota in hepatocellular carcinoma. J Clin Lab Anal 36(7):e24512","journal-title":"J Clin Lab Anal"},{"issue":"5","key":"10431_CR144","first-page":"319","volume":"8","author":"E Jirillo","year":"2002","unstructured":"Jirillo E et al (2002) Review: The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 8(5):319\u2013327","journal-title":"J Endotoxin Res"},{"key":"10431_CR145","doi-asserted-by":"crossref","unstructured":"Kobyliak N, et al (2018) A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","DOI":"10.15403\/jgld.2014.1121.271.kby"},{"issue":"6","key":"10431_CR146","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jhep.2008.02.015","volume":"48","author":"V Stadlbauer","year":"2008","unstructured":"Stadlbauer V et al (2008) Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 48(6):945\u2013951","journal-title":"J Hepatol"},{"issue":"9","key":"10431_CR147","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1177\/0300060518776064","volume":"46","author":"X Xiaoxue","year":"2018","unstructured":"Xiaoxue X et al (2018) Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. J Int Med Res 46(9):3596\u20133604","journal-title":"J Int Med Res"},{"issue":"5","key":"10431_CR148","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/MPG.0000000000000676","volume":"60","author":"T-H Lien","year":"2015","unstructured":"Lien T-H et al (2015) Use of Lactobacillus casei rhamnosus to prevent cholangitis in biliary atresia after Kasai operation. J Pediatr Gastroenterol Nutr 60(5):654\u2013658","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"10431_CR149","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/MEG.0b013e3282f5197e","volume":"20","author":"FP Vleggaar","year":"2008","unstructured":"Vleggaar FP et al (2008) Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 20(7):688\u2013692","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10431_CR150","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","volume":"114","author":"JR Allegretti","year":"2019","unstructured":"Allegretti JR et al (2019) Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Off J Am Coll Gastroenterol| ACG 114(7):1071\u20131079","journal-title":"Off J Am Coll Gastroenterol| ACG"},{"issue":"7","key":"10431_CR151","first-page":"796","volume":"23","author":"C Zeng","year":"2018","unstructured":"Zeng C et al (2018) Clinical effect of entecavir combined with probiotics on treatment of patients with hepatitis B cirrhosis. J Clin Pharm Ther 23(7):796","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"10431_CR152","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/jphp.12247","volume":"66","author":"K Sharma","year":"2014","unstructured":"Sharma K et al (2014) Development of probiotic-based immunoparticles for pulmonary immunization against Hepatitis B. J Pharm Pharmacol 66(11):1526\u20131533","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10431_CR153","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40121-021-00463-1","volume":"10","author":"Y-X Lu","year":"2021","unstructured":"Lu Y-X et al (2021) Effect of additional Clostridium butyricum on the intestinal flora of chronic hepatitis B patients treated with entecavir. Infect Dis Ther 10(3):1519\u20131530","journal-title":"Infect Dis Ther"},{"key":"10431_CR154","unstructured":"Song J, et al (2024) Bifidobacterium mitigates autoimmune hepatitis by regulating IL-33-induced Treg\/Th17 imbalance via the tlr2\/4 signaling pathway"},{"key":"10431_CR155","doi-asserted-by":"crossref","unstructured":"Ma L, et al (2021) Probiotics improve autoimmune hepatitis via gut mycobiota-mediated follicular helper T cells","DOI":"10.21203\/rs.3.rs-900477\/v1"},{"key":"10431_CR156","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1007\/s00253-014-5752-1","volume":"98","author":"J Xin","year":"2014","unstructured":"Xin J et al (2014) Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. Appl Microbiol Biotechnol 98:6817\u20136829","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"10431_CR157","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jnutbio.2013.09.006","volume":"25","author":"GM Raso","year":"2014","unstructured":"Raso GM et al (2014) Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem 25(1):81\u201390","journal-title":"J Nutr Biochem"},{"key":"10431_CR158","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/BF02977800","volume":"28","author":"S-Y Han","year":"2005","unstructured":"Han S-Y et al (2005) Hepatoprotective effect of lactic acid bacteria, inhibitors of \u03b2-glucuronidase production against intestinal microflora. Arch Pharm Res 28:325\u2013329","journal-title":"Arch Pharm Res"},{"issue":"2","key":"10431_CR159","doi-asserted-by":"publisher","first-page":"e0117451","DOI":"10.1371\/journal.pone.0117451","volume":"10","author":"M Hong","year":"2015","unstructured":"Hong M et al (2015) Probiotics (Lactobacillus rhamnosus R0011 and acidophilus R0052) reduce the expression of toll-like receptor 4 in mice with alcoholic liver disease. PLoS ONE 10(2):e0117451","journal-title":"PLoS ONE"},{"issue":"5","key":"10431_CR160","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/gutjnl-2016-313432","volume":"67","author":"C Grander","year":"2018","unstructured":"Grander C et al (2018) Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut 67(5):891\u2013901","journal-title":"Gut"},{"issue":"18","key":"10431_CR161","doi-asserted-by":"publisher","first-page":"14851","DOI":"10.1074\/jbc.M111.314922","volume":"287","author":"Y Zhang","year":"2012","unstructured":"Zhang Y et al (2012) Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury. J Biol Chem 287(18):14851\u201314862","journal-title":"J Biol Chem"},{"key":"10431_CR162","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12602-020-09663-6","volume":"13","author":"C Jantararussamee","year":"2021","unstructured":"Jantararussamee C et al (2021) Hepatoprotective effect of probiotic lactic acid bacteria on thioacetamide-induced liver fibrosis in rats. Probiotics Antimicrob Proteins 13:40\u201350","journal-title":"Probiotics Antimicrob Proteins"},{"key":"10431_CR163","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5487\/TR.2018.34.3.241","volume":"34","author":"YS Roh","year":"2018","unstructured":"Roh YS et al (2018) Lactobacillus aggravate bile duct ligation-induced liver inflammation and fibrosis in mice. Toxicol Res 34:241\u2013247","journal-title":"Toxicol Res"},{"key":"10431_CR164","doi-asserted-by":"publisher","first-page":"100096","DOI":"10.1016\/j.jnim.2019.100096","volume":"16","author":"Z Heydari","year":"2019","unstructured":"Heydari Z et al (2019) Different anti-inflammatory effects of Lactobacillus acidophilus and Bifidobactrum bifidioum in hepatocellular carcinoma cancer mouse through impact on microRNAs and their target genes. J Nutr Intermediary Metab 16:100096","journal-title":"J Nutr Intermediary Metab"},{"key":"10431_CR165","doi-asserted-by":"publisher","first-page":"114314","DOI":"10.1016\/j.fct.2023.114314","volume":"183","author":"I Nenu","year":"2024","unstructured":"Nenu I et al (2024) Lactobacillus rhamnosus probiotic treatment modulates gut and liver inflammatory pathways in a hepatocellular carcinoma murine model. A preliminary study. Food Chem Toxicol 183:114314","journal-title":"Food Chem Toxicol"},{"key":"10431_CR166","doi-asserted-by":"publisher","first-page":"104952","DOI":"10.1016\/j.ebiom.2023.104952","volume":"100","author":"HC Lau","year":"2024","unstructured":"Lau HC et al (2024) Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid. EBioMedicine 100:104952","journal-title":"EBioMedicine"},{"issue":"6","key":"10431_CR167","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","volume":"79","author":"Q Song","year":"2023","unstructured":"Song Q et al (2023) Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol 79(6):1352\u20131365","journal-title":"J Hepatol"},{"issue":"1","key":"10431_CR168","doi-asserted-by":"publisher","first-page":"1946366","DOI":"10.1080\/19490976.2021.1946366","volume":"13","author":"B Li","year":"2021","unstructured":"Li B et al (2021) Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary cholangitis. Gut Microbes 13(1):1946366","journal-title":"Gut Microbes"},{"issue":"2","key":"10431_CR169","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/cei.12843","volume":"186","author":"M Yuksel","year":"2016","unstructured":"Yuksel M et al (2016) The induction of autoimmune hepatitis in the human leucocyte antigen-DR4 non-obese diabetic mice autoimmune hepatitis mouse model. Clin Exp Immunol 186(2):164\u2013176","journal-title":"Clin Exp Immunol"},{"key":"10431_CR170","doi-asserted-by":"publisher","first-page":"115597","DOI":"10.1016\/j.taap.2021.115597","volume":"424","author":"H Wang","year":"2021","unstructured":"Wang H et al (2021) Gut microbiome-host interactions in driving environmental pollutant trichloroethene-mediated autoimmunity. Toxicol Appl Pharmacol 424:115597","journal-title":"Toxicol Appl Pharmacol"},{"key":"10431_CR171","doi-asserted-by":"publisher","first-page":"569104","DOI":"10.3389\/fimmu.2020.569104","volume":"11","author":"H Zhang","year":"2020","unstructured":"Zhang H et al (2020) Bifidobacterium animalis ssp. Lactis 420 mitigates autoimmune hepatitis through regulating intestinal barrier and liver immune cells. Front Immunol 11:569104","journal-title":"Front Immunol"},{"key":"10431_CR172","doi-asserted-by":"publisher","first-page":"108863","DOI":"10.1016\/j.jnutbio.2021.108863","volume":"98","author":"Q Liu","year":"2021","unstructured":"Liu Q et al (2021) Probiotics alleviate autoimmune hepatitis in mice through modulation of gut microbiota and intestinal permeability. J Nutr Biochem 98:108863","journal-title":"J Nutr Biochem"},{"key":"10431_CR173","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-981-19-1946-6_6","volume-title":"Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases: Volume I: Liver, Skin, Thyroid, Rheumatic & Myopathic Diseases","author":"EI Rigopoulou","year":"2022","unstructured":"Rigopoulou EI, Koutsoumpas AL, Bogdanos DP (2022) Microorganisms in pathogenesis and management of primary biliary cholangitis (with focus on molecular mimicry). In: Dwivedi MK et al (eds) Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases: Volume I: Liver, Skin, Thyroid, Rheumatic & Myopathic Diseases. Springer Nature Singapore, Singapore, pp 121\u2013144"},{"key":"10431_CR174","doi-asserted-by":"publisher","first-page":"715852","DOI":"10.3389\/fphys.2021.715852","volume":"12","author":"Y Zheng","year":"2021","unstructured":"Zheng Y et al (2021) The microbiome in autoimmune liver diseases: metagenomic and metabolomic changes. Front Physiol 12:715852","journal-title":"Front Physiol"},{"key":"10431_CR175","doi-asserted-by":"publisher","first-page":"923599","DOI":"10.3389\/fimmu.2022.923599","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L et al (2022) The role of gut microbiota in some liver diseases: from an immunological perspective. Front Immunol 13:923599","journal-title":"Front Immunol"},{"issue":"3","key":"10431_CR176","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","volume":"67","author":"R Tang","year":"2018","unstructured":"Tang R et al (2018) Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 67(3):534\u2013541","journal-title":"Gut"},{"key":"10431_CR177","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2018.09.010","volume":"95","author":"H-D Ma","year":"2018","unstructured":"Ma H-D et al (2018) Gut microbiota translocation promotes autoimmune cholangitis. J Autoimmun 95:47\u201357","journal-title":"J Autoimmun"},{"issue":"7","key":"10431_CR178","doi-asserted-by":"publisher","first-page":"e0198757","DOI":"10.1371\/journal.pone.0198757","volume":"13","author":"K Abe","year":"2018","unstructured":"Abe K et al (2018) Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS ONE 13(7):e0198757","journal-title":"PLoS ONE"},{"issue":"1","key":"10431_CR179","doi-asserted-by":"publisher","first-page":"19705","DOI":"10.1038\/s41598-021-99314-9","volume":"11","author":"S Kitahata","year":"2021","unstructured":"Kitahata S et al (2021) Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis. Sci Rep 11(1):19705","journal-title":"Sci Rep"},{"key":"10431_CR180","doi-asserted-by":"publisher","first-page":"713647","DOI":"10.3389\/fimmu.2021.713647","volume":"12","author":"L Lv","year":"2021","unstructured":"Lv L et al (2021) The salivary microbiota of patients with primary biliary cholangitis is distinctive and pathogenic. Front Immunol 12:713647","journal-title":"Front Immunol"},{"issue":"7","key":"10431_CR181","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/MEG.0b013e3282f5197e","volume":"20","author":"FP Vleggaar","year":"2008","unstructured":"Vleggaar FP, Monkelbaan JF, van Erpecum KJ (2008) Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 20(7):688\u2013692","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10431_CR182","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","volume":"114","author":"JR Allegretti","year":"2019","unstructured":"Allegretti JR et al (2019) Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Off J Am Coll Gastroenterol | ACG 114(7):1071\u20131079","journal-title":"Off J Am Coll Gastroenterol | ACG"},{"issue":"3","key":"10431_CR183","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1096\/fj.14-259515","volume":"29","author":"M Mazagova","year":"2015","unstructured":"Mazagova M et al (2015) Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. Faseb j 29(3):1043\u20131055","journal-title":"Faseb j"},{"issue":"7","key":"10431_CR184","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1073\/pnas.1424775112","volume":"112","author":"H-H Chou","year":"2015","unstructured":"Chou H-H et al (2015) Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Natl Acad Sci 112(7):2175\u20132180","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10431_CR185","first-page":"796","volume":"23","author":"H Airong","year":"2018","unstructured":"Airong H et al (2018) Clinical effect of entecavir combined with probiotics on treatment of patients with hepatitis B cirrhosis. Chin J Clin Pharmacol Ther 23(7):796\u2013801","journal-title":"Chin J Clin Pharmacol Ther"},{"issue":"2","key":"10431_CR186","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack CL et al (2020) Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the american association for the study of liver diseases. Hepatology 72(2):671\u2013722","journal-title":"Hepatology"},{"issue":"1","key":"10431_CR187","first-page":"1","volume":"32","author":"GN Dalekos","year":"2019","unstructured":"Dalekos GN, Koskinas J, Papatheodoridis GV (2019) Hellenic association for the study of the liver clinical practice guidelines: autoimmune hepatitis. Ann Gastroenterol 32(1):1","journal-title":"Ann Gastroenterol"},{"issue":"6957","key":"10431_CR188","first-page":"1323","volume":"271","author":"DC Cowling","year":"1956","unstructured":"Cowling DC, Mackay IR, Taft LI (1956) Lupoid hepatitis. Lancet 271(6957):1323\u20131326","journal-title":"Lancet"},{"issue":"6","key":"10431_CR189","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP et al (2010) Diagnosis and management of autoimmune hepatitis. Hepatology 51(6):2193\u20132213","journal-title":"Hepatology"},{"issue":"6","key":"10431_CR190","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.bpg.2017.09.013","volume":"31","author":"W Cai","year":"2017","unstructured":"Cai W et al (2017) Intestinal microbiome and permeability in patients with autoimmune hepatitis. Best Pract Res Clin Gastroenterol 31(6):669\u2013673","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"10431_CR191","first-page":"5153","volume":"8","author":"R Lin","year":"2015","unstructured":"Lin R et al (2015) Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol 8(5):5153","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"10431_CR192","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/hep.27998","volume":"62","author":"M Yuksel","year":"2015","unstructured":"Yuksel M et al (2015) A novel \u201chumanized mouse\u201d model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 62(5):1536\u20131550","journal-title":"Hepatology"},{"issue":"7","key":"10431_CR193","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/microorganisms8071011","volume":"8","author":"NM Elsherbiny","year":"2020","unstructured":"Elsherbiny NM et al (2020) Autoimmune hepatitis: shifts in gut microbiota and metabolic pathways among Egyptian patients. Microorganisms 8(7):1011","journal-title":"Microorganisms"},{"issue":"3","key":"10431_CR194","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2018-317836","volume":"69","author":"Y Wei","year":"2020","unstructured":"Wei Y et al (2020) Alterations of gut microbiome in autoimmune hepatitis. Gut 69(3):569\u2013577","journal-title":"Gut"},{"issue":"12","key":"10431_CR195","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/apt.15754","volume":"51","author":"T Liwinski","year":"2020","unstructured":"Liwinski T et al (2020) A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis. Aliment Pharmacol Ther 51(12):1417\u20131428","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10431_CR196","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1038\/s41467-019-10703-1","volume":"10","author":"M Hu","year":"2019","unstructured":"Hu M et al (2019) Decreased maternal serum acetate and impaired fetal thymic and regulatory T cell development in preeclampsia. Nat Commun 10(1):3031","journal-title":"Nat Commun"},{"key":"10431_CR197","doi-asserted-by":"publisher","first-page":"102376","DOI":"10.1016\/j.jaut.2019.102376","volume":"110","author":"C Scheinecker","year":"2020","unstructured":"Scheinecker C, G\u00f6schl L, Bonelli M (2020) Treg cells in health and autoimmune diseases: new insights from single cell analysis. J Autoimmun 110:102376","journal-title":"J Autoimmun"},{"issue":"5","key":"10431_CR198","first-page":"591","volume":"138","author":"B Singh","year":"2013","unstructured":"Singh B et al (2013) Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells. Indian J Med Res 138(5):591\u2013594","journal-title":"Indian J Med Res"},{"key":"10431_CR199","doi-asserted-by":"publisher","first-page":"746436","DOI":"10.3389\/fimmu.2021.746436","volume":"12","author":"M Vuerich","year":"2021","unstructured":"Vuerich M et al (2021) Dysfunctional immune regulation in autoimmune hepatitis: from pathogenesis to novel therapies. Front Immunol 12:746436","journal-title":"Front Immunol"},{"key":"10431_CR200","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fimmu.2019.00277","volume":"10","author":"D Parada Venegas","year":"2019","unstructured":"Parada Venegas D et al (2019) Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol 10:277","journal-title":"Front Immunol"},{"key":"10431_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00535-016-1242-9","volume":"52","author":"M Sun","year":"2017","unstructured":"Sun M et al (2017) Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel disease. J Gastroenterol 52:1\u20138","journal-title":"J Gastroenterol"},{"issue":"5","key":"10431_CR202","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/hep4.1326","volume":"3","author":"K Abe","year":"2019","unstructured":"Abe K et al (2019) Interleukin-33\/ST2-mediated inflammation plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis. Hepatol Commun 3(5):670\u2013684","journal-title":"Hepatol Commun"}],"container-title":["Probiotics and Antimicrobial Proteins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-024-10431-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12602-024-10431-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-024-10431-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T07:03:50Z","timestamp":1746515030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12602-024-10431-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":202,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10431"],"URL":"https:\/\/doi.org\/10.1007\/s12602-024-10431-z","relation":{},"ISSN":["1867-1306","1867-1314"],"issn-type":[{"value":"1867-1306","type":"print"},{"value":"1867-1314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"6 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}